Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India

Posted On: 2020-05-26 12:22:21


Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced a new randomized, open-label study to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment strategy. The two antiviral drugs have different mechanism of action, and their combination may demonstrate improved treatment efficacy by effectively tackling high viral loads in patients during early stage of disease.

Early administration of a combination of antiviral medications acting by different mechanisms is desirable for the treatment of COVID-19, since the viral load of SARS-CoV-2 peaks around the time of symptom onset. Thus combining antiviral drugs could result in greater clinical effectiveness and could also prevent, or delay, the emergence of resistance. Favipiravir is an oral antiviral drug approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It has a unique mechanism of action by which it inhibits viral replication: it is converted into an active phosphoribosylated form (favipiravir-RTP) in cells and recognized as a substrate by viral RNA polymerase, thereby inhibiting RNA polymerase activity that is required for viral replication. Umifenovir is another oral antiviral drug licensed for the treatment and prophylaxis of influenza A and B infections in Russia and China.5 Umifenovir impedes the viral attachment to cells and acts as a viral entry inhibitor. Additionally it exhibits modulatory effects on the immune system and induces interferon-production. Hence a combined use of Favipiravir and Umifenovir acting on different mechanisms offers a comprehensive antiviral cover on preentry and post-entry life-cycle of the SARS-CoV-2 virus. Both Favipiravir and Umifenovir inhibited virus infection in vitro and have shown efficacy in COVID-19 clinical trials. The current Glenmark study will examine whether early administration of a combination of Favipiravir and Umifenovir, both acting by different mechanisms, enhances antiviral efficacy on COVID-19 patients.

Commenting on this development, Dr. Monika Tandon, Vice President & Head, Clinical Development Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals Ltd., said, "Combining antiviral agents that have a good safety profile and act on different stages of viral life-cycle is an effective treatment approach to rapidly suppress initial high viral load and lead to overall improvement in clinical parameters. We consider Glenmark's study will be pivotal in leading to identification of highly effective and safe treatments against COVID-19 in India. Beyond its many potential patient treatment benefits, we also hope the combination therapy will reduce infection risk amongst medical professionals and healthcare workers by reducing the duration of virus shedding from treated patients."

Further, Mr. Sujesh Vasudevan, President, India Formulations, Middle East and Africa business, Glenmark Pharmaceuticals Ltd. mentioned "This is another step in our effort is to launch a treatment for COVID-19 patients and we are looking at every possibility. We will do all it takes to ensure accessibility of the product across the country if the clinical trials are successful."

The new combination clinical trial will be called FAITH - (FAvipiravir plus Um | fenovir (efficacy & safety) Trial in Indian Hospital setting). 158 hospitalized patients of moderate COVID-19 infection will be enrolled in the combination study and randomized in two groups: one group receiving Favipiravir and Umifenovir (with standard supportive care); and one group receiving Favipiravir along with standard supportive care. Patients in the arm receiving the drug will receive Faviprivir 1800mg bid and Umifenovir 800 mg bid on Day 1. Thereafter patients would receive Faviprivir 800mg bid and Unifenovir 800mg bid for the remaining course of the treatment. Duration of treatment will be 14 days and patients will be discharged after clinical cure and two consecutive negative tests for COVID-19 based on RT-PCR.

Simultaneously Glenmark is also conducting phase 3 clinical trials of Favipiravir as a COVID-19 monotherapy option with 150 patients, enrolled from 9 leading government and private hospitals across the country. So far 30 patients have been randomised. The monotherapy phase 3 clinical trial results are expected by July/August 2020. Glenmark was the first pharmaceutical company to receive approval from drug regulator DCGI to conduct Favipiravir clinical trials against COVID-19 in India.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.351.8 as compared to the previous close of Rs. 349.85. The total number of shares traded during the day was 288777 in over 6163 trades.

The stock hit an intraday high of Rs. 363.6 and intraday low of 345.1. The net turnover during the day was Rs. 102946449.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Cipla Limited updates on US arm's agreement with Pulmatrix, Inc. USA

The Phoenix Mills Limited board approves fund raising proposal

City Union Bank Ltd to raise Rs. 600 crore through QIP

First Container vessel carrying Export Cargo from India to Bangladesh

MBL's Performance for the year ended 31st March 2020

Den Networks Ltd board to announce first quarter results on July 20, 2020

AU Small Finance Bank Ltd board to approve 1st quarter results on July 23, 2020

Sundaram-Clayton Ltd board to consider Q1FY21 results on July 30, 2020

Kwality Pharmaceuticals Ltd FY2020 consolidated PAT up at Rs. 8.31 crore

Mahindra Holidays & Resorts India Ltd board to approve 1st quarter results on July 31, 2020

Mahindra Lifespaces appoints Parveen Mahtani as Chief Legal Officer

Vedanta launches phase 2 of 'Meal for All' program

Muthoot Finance launches cashback scheme for customers amid COVID-19

Kanchi Karpooram Ltd's expansion delayed, expects to complete by December 2020

International Conveyors Ltd board recommends dividend of Rs. 0.20 for FY20

CRISIL Ltd board to Q2CY2020 results on July 21, 2020

Godrej Industries Ltd board approves raising Rs. 750 crore through NCDs

Aditya Birla Capital's subsidiaries record over four million customer interactions on digital service platforms

Shiva Texyarn launches Medic Virostat Mask at Rs 49

YES BANK FPO of Rs. 15,000 crore opens on July 15, sets Price Band between Rs. 12 to Rs. 13

COVID-19: Liberty Shoes expects 35%-45% fall in revenues this fiscal

Acuite downgrades long term rating of Goa Carbon Ltd

Hatsun Agro Product Ltd board to approve Q1 FY2021 results and interim dividend on July 21, 2020

TVS Motor Company Ltd board to consider 1st quarter results on July 29, 2020

Rajratan Global Wire Ltd board to announce Q1FY21 results on July 21, 2020

5paisa Capital Ltd swings to profit in Q1 FY2020-21

Universal Autofoundry Ltd FY2020 consolidated loss at Rs. 4.05 crore

India Home Loan Ltd Board recommends Final Dividend of Rs. 0.15

HDFC board to announce Q1FY21 results on July 30, 2020

India Home Loan Ltd Q4 FY20 PAT soars to Rs. 1.64 crore

The South India Paper Mills Ltd board to announce Q1FY21 results on July 30, 2020

Asian Oilfield Services Ltd - Business Update

L&T board to announce Q1 FY2021 results on July 22, 2020

HeidelbergCement India Ltd board to announce quarterly results on July 22, 2020

Asahi Songwon Colors Ltd board to approve Q1FY21 results on July 21, 2020

Mr. Subramanian Sarma Inducted as Executive Director on L&T Board, Mr. S V Desai & Mr. T Madhava Das elevated

Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu®

Quick Heal redefines Consumer Security in India

CARE reaffirms rating of Bhageria Industries Limited

Adani Ports and Special Economic Zone Limited updates on ratings from global rating agencies

Birlasoft intelliOpen™ supports safe return-to-work strategies

Morgan Stanley to Consolidate Mumbai GIC operations to a Single Campus at Oberoi Realty's Commerz III Building in Goregaon

Steel Strips Wheels Ltd receives new orders from EU and USA

MBL Infrastructures Ltd gets three favorable arbitration awards

Gitanjali Gems Ltd to be liquidated

Qualcomm Ventures to invest Rs. 730 crore in Jio Platforms

Aarti Surfactants Limited to list on July 14, 2020

Hindustan Unilever Ltd board to consider quarterly results on July 21, 2020

Avenue Supermarts Ltd reports earnings for Q1FY21

Clariant Chemicals' declares Special Interim Dividend of Rs. 140/- per share







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019